-
-
Name
- Daptomycin(Cubicin, LY-164032)
-
Sequence
- decanoyl-Trp-Asn-Asp-Thr-Gly-Orn-Asp-D-Ala-Asp-Gly-D-Ser-Glu(3R-Me)-Asp(Ph(2-NH2))
-
Description
- Daptomycin is a cyclic lipopeptide antibiotic used to treat complicated skin and skin structure infections by susceptible Gram-positive bacteria and bacteremia due to Staphylococcus aureus.
-
-
Target Organism
-
- No MICs found on DRAMP database
-
Reference
-
- Daptomycin and combination daptomycin-ceftaroline as salvage therapy for persistent methicillin-resistant Staphylococcus aureus bacteremia. (PMID: 29508663)
-
Medical use
- Treatment of complicated skin and skin structure infections (cSSSI), Staphylococcus aureus bloodstream infections (bacteremia)
-
Company
- Cubist Pharmaceuticals LLC (Merck & Co.)
-
Stage of Development
- In market
-
- Studies have suggested a direct inhibition of cell membrane/cell wall constituent biosynthesis, including peptidoglycan, uridine diphosphate-N-acid, acetyl-L-alanine, and lipoteichoic acid (LTA).
-